Pedro M. Cruz
Influence of bisphosphonates and monoclonal antibodies
- Medical Resident of Medical Oncology at the Portuguese Oncology Institute of Porto (IPO-Porto).
- PhD student at School of Medicine and Biomedical Sciences (ICBAS).
- Best student of the Medicine Course 2012/2018 of Faculty of Medicine of the University of Coimbra.
Nationality: Portugal
Scientific areas: Cirurgia Oral, Oral surgery
9 of november, from 17h30 until 18h00
Auditorium B
Conference summary
Bisphosphonates and monoclonal antibodies are frequently used in clinical practice, inclusively in the treatment of osteoporosis, of bone loss related to hormonal suppression or long term corticotherapy, of bone metastasis, of multiple myeloma or of hypercalcemia.
Osteonecrosis of the jaw is one of its known possible side effects, being potentially severe and with not fully understood pathophysiology. Its prevention is thus fundamental. It consists essentially in preemptive dental procedures, good oral hygiene and vigilance.
This conference will review the indications for these agents and respective duration, their historical perspective, their pharmacological mechanisms including pharmacokinetics and pharmacodynamics, osteonecrosis of the jaw diagnostic criteria and severity classification, incidence, main pathophysiological models, local and systemic risk factors, prevention, treatment and prognosis. The proceedings for carrying out necessary dental procedures in patients under these agents will also be reviewed.